论文部分内容阅读
目的 :探讨测定血清中可溶性 CD44含量在肺癌中的临床意义。方法 :用酶联免疫吸附试验(EL ISA)检测 45例肺癌患者及 18例正常人血清中可溶性 CD44 s(s CD44 s)和可溶性 CD44 v6 (s CD44 v6 )的含量。结果 :化疗前肺鳞癌和腺癌患者血清 s CD44 s和 s CD44 v6水平明显高于小细胞肺癌 (SCL C)患者和正常组 ,差异非常显著 ;SCL C与正常人比较差异无显著性 ;非小细胞肺癌 (NSCL C) + 期患者血清s CD44 v6明显高于 + 期和正常对照组 (P<0 .0 0 1)。化疗后鳞癌患者血清 s CD44 s、s CD44 v6和腺癌患者血清 s CD44 v6均较化疗前明显下降 (分别为 P<0 .0 0 1,P<0 .0 5 ,P<0 .0 0 1)。结论 :血清 s CD44 s和 s CD44 v6水平可作为诊断 NSCL C及区分肺癌组织学类型的辅助指标 ;NSCL C患者的血清 s CD44 v6水平与其临床分期有关 ;动态检测二者的含量有助于 NSCL C患者的疗效观察
Objective: To investigate the clinical significance of determination of soluble CD44 in serum in lung cancer. Methods: Serum levels of soluble CD44s (sCD44s) and soluble CD44v6 (sCD44v6) were detected by enzyme-linked immunosorbent assay (ELISA) in 45 patients with lung cancer and 18 normal controls. Results: The levels of s-CD44 s and sCD44 v6 in patients with squamous cell carcinoma and adenocarcinoma before chemotherapy were significantly higher than those in patients with small cell lung cancer (SCL C) and normal group, and the difference was significant. There was no significant difference between SCL C and normal subjects. Serum sCD44v6 levels in patients with NSC + C were significantly higher than those in the + and normal controls (P <0.01). Serum sCD44 s, sCD44 v6 and serum s CD44 v6 in patients with squamous cell carcinoma after chemotherapy were significantly lower than those before chemotherapy (P <0.01, P <0.05, P <0. 0 0 1). Conclusion: Serum sCD44 s and sCD44 v6 levels can be used as auxiliary indicators for diagnosis of NSCL C and differentiation of histological types of lung cancer. Serum levels of sCD44 v6 in patients with NSCL C are related to their clinical staging. Dynamic detection of both levels contributes to NSCL C patients with the efficacy of observation